中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 36 Issue 6
Jun.  2020
Turn off MathJax
Article Contents

Clinical effect of terlipressin combined with somatostatin in treatment of esophagogastric variceal bleeding with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2020.06.017
Research funding:

 

  • Published Date: 2020-06-20
  • Objective To investigate the clinical effect of terlipressin combined with somatostatin in the treatment of esophagogastric variceal bleeding( EVB) in patients with liver cirrhosis. Methods A retrospective analysis was performed for the clinical data of 73 patients with liver cirrhosis and EVB who were treated in Department of Gastronenterology and Hepatology,Beijing YouAn Hospital,Capital Medical University,from September 2017 to February 2019. In addition to anti-acid therapy,43 patients were treated with somatostatin,8 patients were treated with terlipressin,and 22 patients were treated with terlipressin combined with somatostatin. The three groups were compared in terms of 24-hour success rate of hemostasis,hemostatic time,early rebleeding rate,delayed rebleeding rate,improvement rate of acute kidney injury( AKI),and half-year cumulative survival rate. A one-way analysis of variance was used for comparison of normally distributed continuous data between the three groups,and the Kruskal-Wallis H rank sum test was used for comparison of non-normally distributed continuous data between the three groups; the chi-square test was used for comparison of categorical data between groups. The cumulative incidence function was used to describe mortality rate,and a competing risk model( Gray's Test) was used for comparison of survival rates between the three groups. Results There were no significant differences between the combination group,the somatostatin group,and the terlipressin group in 24-hour success rate of hemostasis( 54. 5%,41. 9%,and 37. 5%,respectively),hemostatic time [1. 00( 1. 00-3. 00) d,2. 00( 1. 00-3. 00) d,and 2. 00( 1. 00-3. 00) d,respectively],early rebleeding rate( 25%,27. 5%,and 16. 7%,respectively),and delayed rebleeding rate( 16. 7%,27. 3%,and 40%,respectively)( all P > 0. 05). There was no significant difference in the improvement rate of AKI patients after treatment between the combination group and the somatostatin group( 100% vs 50%,P = 0. 429).There was no significant difference in the half-year cumulative survival rate between the three groups( SHR = 1. 40,95% confidence interval:0. 60-3. 27,P = 0. 436). Conclusion Terlipressin combined with somatostatin,somatostatin alone,and terlipressin alone can effectively control EVB in liver cirrhosis and have similar clinical effects. Compared with somatostatin alone,somatostatin combined with terlipressin has a potential advantage in improving AKI.

     

  • loading
  • [1] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Endoscopy,Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol,2016,32(2):203-219.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J].临床肝胆病杂志,2016,32(2):203-219.
    [2] European Association for the Study of the Liver. EASL Clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460.
    [3] XIA ZX,ZHANG ZF. The efficacy of Tripsin combined growth inhibition in treatment of decompensated liver cirrhosis combined with upper gastrointestinal bleeding[J]. Drug Eval Res,2017,40(12):1745-1748.(in Chinese)夏正新,张志飞.特利加压素联合生长抑素治疗肝硬化失代偿期并急性上消化道大出血的疗效观察[J].药物评价研究,2017,40(12):1745-1748.
    [4] ZHANG L,ZHANG R,LIU FL,et al. Terlipressin combined with somatostatin in treatment of hemorrhage of esophagogastric varices due to portal hypertension in liver cirrhosis[J]. Chin J Bases Clin Gen Surg,2014,21(11):1436-1438.(in Chinese)张磊,章锐,刘飞龙,等.特利加压素联合生长抑素治疗门静脉高压食管胃底曲张静脉破裂出血[J].中国普外基础与临床杂志,2014,21(11):1436-1438.
    [5] KRAG A,BORUP T,MLLER S,et al. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome[J]. Adv Ther,2008,25(11):1105-1140.
    [6] ANGELI P,GINES P,WONG F,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. Gut,2015,64(4):531-537.
    [7] GARCIA-TSAO G,BOSCH J. Management of varices and variceal hemorrhage in cirrhosis[J]. N Engl J Med,2010,362(9):823-832.
    [8] GARCA-PAGN JC,REVERTER E,ABRALDES JG,et al. Acute variceal bleeding[J]. Semin Respir Crit Care Med,2012,33(1):46-54.
    [9] PEDRETTI G,ELIA G,CALZETTI C,et al. Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding[J]. Clin Investig,1994,72(9):653-659.
    [10] HUNG TH,TSAI CC,TSENK GC,et al. No mortality difference following treatment with terlipressin or somatostatin in cirrhotic patients with gastric variceal hemorrhage[J]. Saudi J Gastroenterol,2016,22(3):220-225.
    [11] SEO YS,PARK SY,KIM MY,et al. Lack of difference among terlipressin,somatostatin,and octreotide in the control of acute gastroesophageal variceal hemorrhage[J]. Hepatology,2014,60(3):954-963.
    [12] SRIDHARAN K,SIVARAMAKRISHNAN G. Vasoactive agents for the management of variceal bleeding:A mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials[J]. Drug Res(Stuttg),2019,69(9):487-495.
    [13] JINDAL A,BHADORIA AS,MAIWALL R,et al. Evaluation of acute kidney injury and its response to terlipressin in patients with acute-on-chronic liver failure[J]. Liver Int,2016,36(1):59-67.
    [14] ZANG H,LIU F,LIU H,et al. Incidence,risk factors and outcomes of acute kidney injury(AKI)in patients with acuteon-chronic liver failure(ACLF)of underlying cirrhosis[J].Hepatol Int,2016,10(5):807-818.
    [15] SUN DQ,ZHENG CF,LIU WY,et al. AKI-CLIF-SOFA:A novel prognostic score for critically ill cirrhotic patients with acute kidney injury[J]. Aging(Albany NY),2017,9(1):286-296.
    [16] SHETTY S,NAGARAJU SP,SHENOY S,et al. Acute kidney injury in patients with cirrhosis of liver:Clinical profile and predictors of outcome[J]. Indian J Gastroenterol,2018,37(3):248-254.
    [17] SHI X,ZHU P,YAN G,et al. Clinical characteristics and longterm outcome of acute kidney injury in patients with HBV-related acute-on-chronic liver failure[J]. J Viral Hepat,2016,23(11):920-929.
    [18] DURAND F,OLSON JC,NADIM MK. Renal dysfunction and cirrhosis[J]. Curr Opin Crit Care,2017,23(6):457-462.
    [19] BUCSICS T,KRONES E. Renal dysfunction in cirrhosis:Acute kidney injury and the hepatorenal syndrome[J]. Gastroenterol Rep(Oxf),2017,5(2):127-137.
    [20] ZHAI XR,XU X,CHEN J,et al. Effect of response at 48 hours of treatment of acute kidney injury on short-term prognosis of hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol,2019,35(9):2001-2005.(in Chinese)翟兴冉,许祥,陈婧,等.急性肾损伤治疗48小时应答与否对HBV相关慢加急性肝衰竭短期预后的影响[J].临床肝胆病杂志,2019,35(9):2001-2005.
    [21] CHENG Y,LAN Y,JIA QB. Tenet vasopressin hemodynamics in liver cirrhosis patients with upper gastrointestinal bleeding[J]. J Clin Exp Med,2018,17(22):2419-2422.(in Chinese)程远,兰宇,贾绮滨.特利加压素对肝硬化上消化道出血患者血流动力学的影响[J].临床和实验医学杂志,2018,17(22):2419-2422.
    [22] ARORA V,MAIWALL R,RAJAN V,et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J]. Hepatology,2020,71(2):600-610.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (982) PDF downloads(201) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return